Abbreviations AKI Acute kidney injury AKIN Acute kidney injury network Alk3 Acitvin-like kinase 3 AP Alkaline phosphatase Article highlights BM-MSCs Bone marrow derrived mesenchymal stem cells BMP Bone morphogenetic protein Comprehensive CKD Chronic kidney disease review of agents currently CRP C-reactive protein CS-AKI Cardiac surgery associated AKI in clinical trial for CypD Cyclophilin D transplant, sterile and DAMP Damage associated molecular pattern DBD Donation after brain stem death sepsis associated AKI DGF Delayed graft function Up to date eGFR Estimated glomerular filtration rate information on trial ESRF End-stage renal failure HGF Hepatocyte growth factor progress HO-1 Heme-oxygenase-1 Review of AC607 ICU Intensive care unit IL Interleukin and ABT-719 two recent IRI Ischemia reperfusion injury failed drugs KDIGO Kidney disease improving global outcomes Integration of new KIM-1 Kidney injury molecule 1 LPS Lipopolysaccharide pathophysiological MCP-1 Monocyte chemoattractant protein 1 understanding of cell MLKL Mixed lineage kinase like domain death pathways with MPTP Mitochondrial permeability transition pore MSH Melanocortin stimulating hormone current agents NGAL Neutrophil Gelatinase-Associated Lipocalcin Expert opinion on NSTI Necrotising soft tissue infection PARP-1 Poly[ADP-ribose] polymerase 1 the way forward in PBMC Peripheral blood mononucear cells therapeutics for AKI PTEC Proximal tubular epithelial cell RCT Randomised controlled trial recAP Recombinant alkaline phosphatase Receptor interacting serine-threonine protein RIPK kinase ROS Reactive oxygen species RRT Renal replacement therapy SA-AKI Sepsis associated AKI TGFB Transforming growth factor beta TGF-β Transforming growth factor beta TLR Toll-like receptor
Abbreviations AKI Acute kidney injury AKIN Acute kidney injury network Alk3 Acitvin-like kinase 3 AP Alkaline phosphatase BM-MSCs Bone marrow derrived mesenchymal stem cells BMP Bone morphogenetic protein CKD Chronic kidney disease CRP C-reactive protein CS-AKI Cardiac surgery associated AKI CypD Cyclophilin D DAMP Damage associated molecular pattern DBD Donation after brain stem death DGF Delayed graft function eGFR Estimated glomerular filtration rate ESRF End-stage renal failure HGF Hepatocyte growth factor HO-1 Heme-oxygenase-1 ICU Intensive care unit IL Interleukin IRI Ischemia reperfusion injury KDIGO Kidney disease improving global outcomes KIM-1 Kidney injury molecule 1 LPS Lipopolysaccharide MCP-1 Monocyte chemoattractant protein 1 MLKL Mixed lineage kinase like domain MPTP Mitochondrial permeability transition pore MSH Melanocortin stimulating hormone NGAL Neutrophil Gelatinase-Associated Lipocalcin NSTI Necrotising soft tissue infection PARP-1 Poly[ADP-ribose] polymerase 1 PBMC Peripheral blood mononucear cells PTEC Proximal tubular epithelial cell RCT Randomised controlled trial recAP Recombinant alkaline phosphatase RIPK Receptor interacting serine-threonine protein kinase ROS Reactive oxygen species RRT Renal replacement therapy SA-AKI Sepsis associated AKI TGFB Transforming growth factor beta TGF-β Transforming growth factor beta TLR Toll-like receptor Article highlights Comprehensive review of agents currently in clinical trial for transplant, sterile and sepsis associated AKI Up to date information on trial progress Review of AC607 and ABT-719 two recent failed drugs Integration of new pathophysiological understanding of cell death pathways with current agents Expert opinion on the way forward in therapeutics for AKI